AzTrials
AzTrials

Systemic Inflammatory Response Syndrome (SIRS)MicorSIRSNCT03288610

Prediction of Inflammatory Response and Hypotensive Syndrome After Cardiac Surgery by Preoperative Copeptin Level

An observational study of Systemic Inflammatory Response Syndrome (SIRS) and Postoperative Vasodilation Syndrome, run by University Hospital, Montpellier at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to find a preoperative biomarker before cardiac surgery with cardiopulmonary bypass related to severe postoperative inflammatory response and circulatory complications. Read more about this study

Who is it for?
Ages 18 to 81 years
What is being tested?
Preoperative copeptin level
Type of treatment
Injection or infusion
How many people
200 participants
Where
1 siteFrance
Study dates
Jan 2017to Aug 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 81 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients hospitalized and scheduled for cardiac surgery

Who may be able to join

  • Elective surgery
  • Scheduled time of at least 24 hours
  • Cardiopulmonary bypass

Who cannot join

  • Urgent surgery within 24 hours of hospital admission
  • Chronic renal failure with preoperative glomerular filtration rate below 45 ml/min
  • Ongoing sepsis (ie uncontrolled endocarditis)
  • Immunosuppressive therapy (solid organ transplant recipient)
  • Previously included in this study

Trial locations and contacts

1 site in 1 country.

France1 site
  • Department of critical care, Arnaud de Villeneuve Hospital

    Montpellier, 34295

Other trials in France

About this study

Official title: Prognostic Value of Copeptin Level Before Cardiac Surgery and Involvement in Systemic Inflammatory Response Syndrome After Cardiopulmonary Bypass

The purpose of this study is to find a preoperative biomarker before cardiac surgery with cardiopulmonary bypass related to severe postoperative inflammatory response and circulatory complications. The investigators hypothesize that an increase of the preoperative stimulation of vasopressinergic system (in response to acute or chronic conditions) could lead to a microcirculatory dysfunction and favor the occurrence of vasodilatation during and after CPB and increase the symptoms of an inflammatory response after CPB. By defining a high risk population, a targeted strategy of monitoring and early or preventive treatment could improve postoperative prognosis.

Read the detailed description

The occurrence of a severe systemic inflammatory response syndrome (SIRS) after elective cardiac surgery with cardiopulmonary bypass (CPB) is estimated at about 20% of cases and is characterized by hemodynamic changes (tachycardia, hypotension, hypovolemia). It is also responsible for vasodilation with impaired microcirculation involving increased morbidity and mortality associated with organ dysfunction and the risk of bacterial translocation. However, the participation of vasopressinergic system in the functional impairment of microcirculation is unclear.

Copeptin is considered a marker of vasopressin secretion, deriving from the same precursor, being more stable and easy to dose. In a previous study of 64 patients with CPB, the investigators have shown that high copeptin preoperative levels are associated with the occurrence of vasodilatation syndrome after cardiac surgery (incidence 15%) with a relative deficiency of postoperative vasopressin.

Microcirculatory alterations can be explored through the study of tissue oxygenation by NIRS (StO2) at rest and in response to a hypoxic challenge (provided by brief vascular occlusion). In septic shock, altered recovery slopes of tissue oxygenation are associated with poor prognosis. The investigators could find similar impact on prognosis in cardiogenic shock if first hours of care did not improve this recovery slope.

The investigators hypothesize that an increase of the preoperative stimulation of vasopressinergic system (in response to acute or chronic conditions) could favor the occurrence of vasodilatation during and after CPB and increase the symptoms of an inflammatory response after CPB. The involvement of vasopressin in microcirculatory dysfunction is unknown.

This is a validation study of a predictive test for pathophysiology and prognosis. This study will be monocentric, prospective and observational in routine care.

The main end point of the study is to predict the onset of severe SIRS or postoperative vasodilation syndrome after CPB by the preoperative plasma copeptin level in a cardiac surgery population.

The secondary objectives are to assess the incidences of microcirculatory dysfunction, shock and organs failure after CPB, to determine the postoperative copeptin kinetics for patients with severe SIRS, to evaluate the prognosis with the ICU length of stay and D28 mortality.

Data are recorded prospectively on a paper case report form by ICU physicians in charge of the patients on the basis of clinical observation and electronic medical records. Quality assurance, monitoring and auditing are provided by the study promotor. Data will be checked by the main investigator to assess the accuracy and completeness of entered data into the CRF.

Patients are recruited during the preoperative period after screening of inclusion and exclusion criteria, delivering information and obtaining written consent.

Considering an expected sensitivity for predicting SIRS by preoperative copeptin on the order of 80%, the number of cases (subjects with severe SIRS) to be included for obtaining an estimate of the sensitivity with a lower limit of 95% to 55% is placed in 42 cases. Considering an incidence of severe SIRS at 20%, the total number of patients to be included in the study is 200. In our center the investigators perform 700 CPB / year, 70% met the criteria for inclusion.

For the primary objective, the predictive performance of preoperative copeptin for the occurrence of post-CPB severe SIRS will be evaluated by the construction of a ROC curve with finding an optimal threshold maximizing sensitivity and specificity (calculation of the Youden index) to be then estimated with their 95% confidence interval.

Regarding the secondary objectives, copeptin levels will be compared according to the presence of postoperative microcirculatory dysfunction, hemodynamic failure, organ dysfunction and preoperative factors using a reduced gap test. Univariate and multivariate analysis using linear regressions will be carried out to find the preoperative factors associated significantly and independently to high copeptin level. The postoperative kinetics of copeptin will be modeled using mixed linear regressions with an intercept +/- a random slope and taking into account the intra-individual correlation of the assays. The prognostic value of preoperative copeptin and postoperative StO2 recovery slope on D28 mortality will be analyzed using the ROC curve, determination of an optimal threshold using the Youden index and then calculating Sensitivity and specificity with their 95% confidence interval.

Being tested
Preoperative copeptin level
Keywords
Copeptin, Vasopressin, Microcirculation, Inflammation, Vasodilation, Cardiopulmonary bypass
Medical subject headings
Systemic Inflammatory Response Syndrome, Fractures, Stress, Diabetes Insipidus, Inflammation, Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Preoperative copeptin levelDiagnostic test

    Also called Biomarker of vasopressin secretion, Systemic Inflammatory Response Syndrome (SIRS), Postoperative vasodilation syndrome, Stress response

    Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.

Study groups in NCT03288610
Study groupRoleWhat they receive
With inflammatory responsePatients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome. Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3. Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2. Patients without postoperative severe SIRS and without postoperative vasodilation syndrome
Receives: Diagnostic Test: Preoperative copeptin level

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Preoperative copeptin level

    Plasmatic copeptine will be measured from routine blood sample on heparinazed tubes. The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France). A level above the 97° percentile of referent population will be considered pathological.

    Measured: Preoperative 24 hours

Secondary outcomes (13)
  1. Postoperative microcirculatory impairment

    Tissue oxygen saturation (STO2) measured at the thenar eminence by NIRS (Inspectra 650, Hutchinson Technologies) with application of a 3 min vascular occlusion test to measure the occlusion slope, the recovery slope and the hyperemic rebound. Microcirculatory dysfunction is defined by a recovery slope below 3%/s.

    Measured: Within 2h of admission in intensive care unit, before weaning of sedation and mechanical ventilation

  2. Occurrence of SIRS using classical definition

    SIRS is classically defined when 2 of the following criteria are met together: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.

    Measured: First postoperative 24 hours

  3. Postoperative hemodynamical impairment

    Occurrence of

    • A postoperative vasodilation syndrome defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2
    • a postoperative low cardiac output syndrome defined by cardiac index below 2.2 L/min/m2 without hypovolemia,
    • a tissue hypoxia assessed by 2 consecutive lactate level above 2.2 mmol/l,
    • an hemorrhagic shock or
    • a septic shock.

    Measured: First postoperative 24 hours

  4. Perioperative copeptin kinetics

    Plasmatic copeptin will be measured from routine blood sample on heparinized tubes. The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France). A level above the 97° percentile of referent population will be considered pathological.

    Measured: 24 hours before the operation until admission intensive care unit

  5. Perioperative copeptin kinetics

    Plasmatic copeptin will be measured from routine blood sample on heparinized tubes. The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France). A level above the 97° percentile of referent population will be considered pathological.

    Measured: postoperative day

  6. Global organs dysfunction

    Assessed by the Sequencial Organ Failure Assessment (SOFA) score calculated at the postoperative day

    Measured: First postoperative 24 hours

  7. Lengh of mechanical ventilation

    Length (hours) of postoperative invasive mechanical ventilation

    Measured: Up to 28 days

  8. Acute kidney injury

    Defined and classified according to KDIGO criteria

    Measured: Up to 28 days

  9. Renal replacement therapy

    Incidence of patients requiring renal replacement therapy in ICU due to postoperative acute kidney injury

    Measured: Up to 28 days

  10. Intensive Care Unit stay

    Length (days) of postoperative intensive care unit stay

    Measured: through study completion, an average of 3 month

  11. Hospital stay

    Length (days) of postoperative hospital stay before current care ward discharge (excluding rehabilitation time)

    Measured: through study completion, an average of 3 month

  12. Intensive Care Unit mortality rate

    Intensive care unit mortality rate : death before ICU discharge

    Measured: Up to 28 days

  13. Day 28 mortality rate

    Overall mortality rate at 28 days after surgery

    Measured: Up to 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2017
  2. Study startJan 2017
  3. Primary completionJul 2017
  4. Study completionAug 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03288610
Sponsor's protocol ID
9754
Acronym
MicorSIRS
Status last verified
May 2017
First submitted
9 May 2017
Last updated
25 Sep 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • MacCallum NS, Finney SJ, Gordon SE, Quinlan GJ, Evans TW. Modified criteria for the systemic inflammatory response syndrome improves their utility following cardiac surgery. Chest. 2014 Jun;145(6):1197-1203. doi: 10.1378/chest.13-1023.

    PubMed 24576975
  • Colson PH, Bernard C, Struck J, Morgenthaler NG, Albat B, Guillon G. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care. 2011;15(5):R255. doi: 10.1186/cc10516. Epub 2011 Oct 25.

    PubMed 22026977

Questions about this trial

What is this clinical trial studying?

An observational study of Systemic Inflammatory Response Syndrome (SIRS) and Postoperative Vasodilation Syndrome, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Preoperative copeptin level (time frame: Preoperative 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03288610, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in